On October 14, 2024, the FDA approved a 320-mg single dose of bimekizumab-bkzx (Bimzelx; UCB) in a 2-mL prefilled syringe and autoinjector; both forms are now commercially available in the US.
Jeff Stark, MD
Advertisement
Articles by Jeff Stark, MD
Advertisement
Latest Updated Articles
Conditional Economic Incentives Could Be Effective in Improving Adherence to Long-Acting PrEP in Transgender AdultsPublished: August 18th 2025 | Updated: August 25th 2025
Semaglutide Not Associated With Increased Risk of Eye DisordersPublished: August 19th 2025 | Updated: August 22nd 2025
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?Published: June 6th 2025 | Updated: August 18th 2025
Report Reveals Mounting Burdens of Drug Shortages on US Health SystemPublished: June 27th 2025 | Updated: July 1st 2025
Managed Care Reflections: Insights From Richard J. Gilfillan, MD; and Donald M. Berwick, MD, MPPPublished: February 20th 2025 | Updated: February 21st 2025
FDA Proposal Aims to Reduce Smoking Addiction and SCLC CasesPublished: January 16th 2025 | Updated: January 29th 2025
Advertisement
Advertisement
Trending on AJMC
1
West Coast Health Alliance Releases First Vaccine Guidelines, Aiming to Replace CDC Recommendations
2
Hospitals in Underserved Communities Less Likely to Adopt Health Information Technology
3
Metabolic Issues More Common in Patients With HIV
4
Sotatercept Shows Right Heart Gains in PAH: Anjali Vaidya, MD
5
